Barbara Vogg

419 total citations
8 papers, 155 citations indexed

About

Barbara Vogg is a scholar working on Physiology, Pharmacology and Computational Theory and Mathematics. According to data from OpenAlex, Barbara Vogg has authored 8 papers receiving a total of 155 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Physiology, 3 papers in Pharmacology and 3 papers in Computational Theory and Mathematics. Recurrent topics in Barbara Vogg's work include Alzheimer's disease research and treatments (3 papers), Computational Drug Discovery Methods (3 papers) and Cholinesterase and Neurodegenerative Diseases (3 papers). Barbara Vogg is often cited by papers focused on Alzheimer's disease research and treatments (3 papers), Computational Drug Discovery Methods (3 papers) and Cholinesterase and Neurodegenerative Diseases (3 papers). Barbara Vogg collaborates with scholars based in Switzerland, United Kingdom and Belgium. Barbara Vogg's co-authors include Katrine E. Nielsen, Jens Peter Jacobsen, Poul Nielsen, Wilfried Frieauff, Laura H. Jacobson, Heinrich Rueeger, Grit Laue, Ulf Neumann, Derya R. Shimshek and Karen Beltz and has published in prestigious journals such as Journal of Bone and Mineral Research, Tetrahedron and European Journal of Pharmaceutical Sciences.

In The Last Decade

Barbara Vogg

8 papers receiving 151 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Barbara Vogg Switzerland	4	78	70	37	37	19	8	155
Joan Albert Vericat Germany	3	106 1.4×	139 2.0×	75 2.0×	39 1.1×	12 0.6×	3	259
Jill Steidl‐Nichols United States	10	90 1.2×	146 2.1×	50 1.4×	41 1.1×	6 0.3×	15	288
Karen Beltz Switzerland	7	120 1.5×	78 1.1×	63 1.7×	74 2.0×	14 0.7×	10	242
Elena Speretta United Kingdom	6	83 1.1×	95 1.4×	48 1.3×	20 0.5×	7 0.4×	8	191
Michele Sanguanini United Kingdom	5	157 2.0×	154 2.2×	18 0.5×	21 0.6×	7 0.4×	6	236
Hilda Solanoy United States	4	30 0.4×	67 1.0×	16 0.4×	16 0.4×	21 1.1×	4	158
Virginia Castillo Cano Spain	3	107 1.4×	103 1.5×	30 0.8×	38 1.0×	3 0.2×	3	154
Yumiko Uno Japan	8	80 1.0×	177 2.5×	62 1.7×	30 0.8×	61 3.2×	13	307
Xuejian Feng China	8	95 1.2×	134 1.9×	21 0.6×	14 0.4×	17 0.9×	12	286
Sophie Allauzen United States	6	103 1.3×	107 1.5×	12 0.3×	19 0.5×	7 0.4×	8	205

Countries citing papers authored by Barbara Vogg

Since Specialization

Citations

This map shows the geographic impact of Barbara Vogg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Barbara Vogg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Barbara Vogg more than expected).

Fields of papers citing papers by Barbara Vogg

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Barbara Vogg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Barbara Vogg. The network helps show where Barbara Vogg may publish in the future.

Co-authorship network of co-authors of Barbara Vogg

This figure shows the co-authorship network connecting the top 25 collaborators of Barbara Vogg. A scholar is included among the top collaborators of Barbara Vogg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Barbara Vogg. Barbara Vogg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

Jeka, Sławomir, Eva Dokoupilová, Alan Kivitz, et al.. (2024). Equivalence trial of proposed denosumab biosimilar GP2411 and reference denosumab in postmenopausal osteoporosis: the ROSALIA study. Journal of Bone and Mineral Research. 39(3). 202–210. 6 indexed citations

Vogg, Barbara, Johann Poetzl, Alan Kivitz, et al.. (2024). The Totality of Evidence for SDZ-deno: A Biosimilar to Reference Denosumab. Clinical Therapeutics. 46(11). 916–926. 2 indexed citations

Vogg, Barbara, et al.. (2024). Pharmacokinetics and pharmacodynamics of the proposed biosimilar denosumab GP2411 and reference denosumab in healthy males. Expert Opinion on Biological Therapy. 24(1-2). 91–100. 3 indexed citations

Neumann, Ulf, Laura H. Jacobson, Karen Beltz, et al.. (2016). P1‐083: Preclinical Pharmacology of Bace Inhibitor CNP520. Alzheimer s & Dementia. 12(7S_Part_9). 1 indexed citations

Neumann, Ulf, Heinrich Rueeger, Rainer Machauer, et al.. (2015). A novel BACE inhibitor NB-360 shows a superior pharmacological profile and robust reduction of amyloid-β and neuroinflammation in APP transgenic mice. Molecular Neurodegeneration. 10(1). 44–44. 92 indexed citations

Gabrielsson, Johan, Stephan Hjorth, Barbara Vogg, et al.. (2014). Modeling and design of challenge tests: Inflammatory and metabolic biomarker study examples. European Journal of Pharmaceutical Sciences. 67. 144–159. 9 indexed citations

Neumann, Ulf, Heinrich Rueeger, Rainer Machauer, et al.. (2014). P4‐363: THE BACE INHIBITOR NB‐360 HAS EXCELLENT BRAIN PENETRATION AND EFFICACY ON AMYLOID‐B LOAD IN ANIMAL MODELS. Alzheimer s & Dementia. 10(4S_Part_16). 1 indexed citations

Nielsen, Katrine E., et al.. (2001). Synthesis and NMR-studies of dinucleotides with conformationally restricted cyclic phosphotriester linkages. Tetrahedron. 57(51). 10191–10201. 41 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact